<DOC>
	<DOCNO>NCT02728648</DOCNO>
	<brief_summary>Oxycodone clinical use decade . It effective alternative morphine moderate severe acute chronic pain find improve quality life . The drug use parenterally orally perioperative analgesia cancer pain relief ( Kalso 2005 ) . Despite long clinical experience , prescribe error misuse may lead addiction accidental overdose ( Berling et al . 2013 , Boyle Dosenbaum 2014 ) . Currently , little know pharmacokinetic property intravenous oxycodone among paediatric patient region even though drug use child country Finland . Therefore , pharmacokinetic-pharmacodynamic study oxycodone among Malaysian pediatric patient warrant .</brief_summary>
	<brief_title>Population Pharmacokinetic-Pharmacodynamic Study Intravenous Oxycodone Children</brief_title>
	<detailed_description>Oxycodone ( 14-hydroxy-7,8 dihydrocodeinone ) strong , semisynthetic thebaine derivative µ-opioid receptor agonist . This drug effective alternative morphine moderate-to-severe pain . Oxycodone use parenterally orally perioperative analgesia cancer pain relief . The drug long analgesic action morphine . In term analgesic potency , intravenous oxycodone 1.6 time The adverse effect oxycodone mostly similar opioids . Oxycodone , however , cause histamine release . The drug induce less nausea vomiting , less sedate , less central nervous system excitatory effect morphine ( Kalso et al.1991 ) . A large subject variability pharmacokinetic property oxycodone observe . The variability could attribute difference body size age-related difference drug elimination organ system function . A 2-compatment first-order open model describe oxycodone pharmacokinetics Finnish child ( age 5.4±2.1 year ) intravenous bolus dose 0.1 mg kg-1 post ophthalmic surgery pain relief ( Olkkola et al . 1994 ) . The author report mean clearance ( CL ) steady state volume distribution ( Vss ) oxycodone 15.2 mL min-1 kg-1 ( 0.912 L h-1 kg-1 ) 2.1 L kg-1 respectively . A great ventilator depression comparable analgesic dos opioids also observe . A pharmacokinetic study ( Poyhia et al . 1991 ) carry 9 young Finnish adult surgical patient reveals clearance 0.78 L min-1 ( 46.8 L h-1 ) volume distribution ( V ) 2.60 L kg-1 . The mean AUC ( t=0,12 ) ratio noroxycodone ( main metabolite ) oxycodone 0.33 . In study 69 Japanese adult ( mean age 66 year , mean weight 52.8 kg ) receive intravenous oxycodone cancer pain relief , one-compartment first-order open model describe pharmacokinetics oxycodone . The mean CL volume distribution ( V ) 24.6 L h-1 214 L 4.053 L kg-1 ( Kokubun et al . 2014 ) . Often drug concentration saliva reflect free drug concentration plasma . Moreover , saliva collect rapidly easily . Therefore saliva may alternative body fluid study exposure drug body especially young child .</detailed_description>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Aged 3 17 year Generally healthy document medical history ( ASA 1II ) Opioidnaïve Patient schedule surgical procedure/procedures is/are expect require analgesia opiate level medication . Patient remain hospitalized least 24 hour dose study drug . A negative urine pregnancy test screening female childbearing potential Patient lactate breastfeed female Patient know allergy oxycodone ingredient oxycodone dosage form .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pain Management</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>